Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

Conditions:   Metastatic Cancer;   Melanoma;   Colon Cancer;   Differentiated Thyroid Cancer;   Hepatocellular Carcinoma;   Renal Cell Carcinoma;   Metastatic Melanoma;   HCC;   Metastatic Colon Cancer
Intervention:   Other: Solar Simulator
Sponsor:   University of Arizona
Recruiting - verified June 2017

http://ift.tt/2qXBFMV